Description
R-Pharm Germany has set up a biotechnical plant at its Illertissen site. Driven by the pandemic situation, a production area for vaccines and one for monoclonal antibodies (MAB) were established. In a very ambitious timeline, all the necessary infrastructure and supporting functions were also built.
Speaker(s):
